In the past week, ESPR stock has gone down by -0.85%, with a monthly decline of -14.52% and a quarterly surge of 31.59%. The volatility ratio for the week is 5.79%, and the volatility levels for the last 30 days are 13.05% for Esperion Therapeutics Inc The simple moving average for the past 20 days is -19.31% for ESPR’s stock, with a -3.06% simple moving average for the past 200 days.
Is It Worth Investing in Esperion Therapeutics Inc (NASDAQ: ESPR) Right Now?
The 36-month beta value for ESPR is also noteworthy at 1.02. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ESPR is 195.08M, and at present, short sellers hold a 13.06% of that float. The average trading volume of ESPR on December 30, 2024 was 5.68M shares.
ESPR) stock’s latest price update
Esperion Therapeutics Inc (NASDAQ: ESPR) has seen a decline in its stock price by -4.77 in relation to its previous close of 2.28. However, the company has experienced a -0.85% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-18 that – $150 Million Senior Secured Term Loan Credit Facility and New $100 Million Convertible Note to Repay Significant Portion of Existing $265 Million Convertible Debt –
Analysts’ Opinion of ESPR
Many brokerage firms have already submitted their reports for ESPR stocks, with Goldman repeating the rating for ESPR by listing it as a “Neutral.” The predicted price for ESPR in the upcoming period, according to Goldman is $4 based on the research report published on December 18, 2024 of the current year 2024.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see ESPR reach a price target of $8. The rating they have provided for ESPR stocks is “Overweight” according to the report published on December 17th, 2024.
BofA Securities gave a rating of “Underperform” to ESPR, setting the target price at $2.50 in the report published on June 20th of the current year.
ESPR Trading at -10.44% from the 50-Day Moving Average
After a stumble in the market that brought ESPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.89% of loss for the given period.
Volatility was left at 13.05%, however, over the last 30 days, the volatility rate increased by 5.79%, as shares sank -22.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.84% upper at present.
During the last 5 trading sessions, ESPR fell by -0.91%, which changed the moving average for the period of 200-days by +5.85% in comparison to the 20-day moving average, which settled at $2.69. In addition, Esperion Therapeutics Inc saw -27.38% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ESPR starting from Halladay Benjamin, who sale 3,245 shares at the price of $2.42 back on Dec 17 ’24. After this action, Halladay Benjamin now owns 240,691 shares of Esperion Therapeutics Inc, valued at $7,866 using the latest closing price.
Warren Eric, the Chief Commercial Officer of Esperion Therapeutics Inc, sale 2,234 shares at $2.43 during a trade that took place back on Dec 17 ’24, which means that Warren Eric is holding 160,121 shares at $5,426 based on the most recent closing price.
Stock Fundamentals for ESPR
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.82 for the gross margin
The net margin for Esperion Therapeutics Inc stands at -0.29. The total capital return value is set at 0.11.
Based on Esperion Therapeutics Inc (ESPR), the company’s capital structure generated -2.45 points at debt to capital in total, while cash flow to debt ratio is standing at -0.1. The debt to equity ratio resting at -0.71. The interest coverage ratio of the stock is 0.28.
Currently, EBITDA for the company is -150.11 million with net debt to EBITDA at -4.31. When we switch over and look at the enterprise to sales, we see a ratio of 1.87. The receivables turnover for the company is 4.36for trailing twelve months and the total asset turnover is 0.94. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.85.
Conclusion
In summary, Esperion Therapeutics Inc (ESPR) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
